SAN DIEGO, April 12, 2016 /PRNewswire/ -- OncoSec Medical
Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, today announced that
preclinical results from OncoSec's collaboration with Heat
Biologics, Inc. will be featured as a poster presentation at the
upcoming American Association of Cancer Research (AACR) Annual
Meeting to be held on April 16-20,
2016 in New Orleans,
LA.
Details of the poster presentation are as follows:
- Abstract Title: In vivo intra-tumoral electroporation of
Gp96-Ig/Fc-OX40L stimulates CD8+ T cell cross-priming to tumor
specific neoantigens (Abstract ID #567)
- Session Title: Immune Modulating Agents 1
- Date and Time: April 17,
2016 at 1:00 p.m. –
5:00 p.m. CT
- Location: Section 26
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies for the treatment of cancer. The Company's
investigational technology, ImmunoPulse™, is designed to enhance
the local delivery and uptake of DNA-based immune-targeting agents,
such as interleukin-12 (IL-12). In Phase I and II clinical trials,
OncoSec's lead program, ImmunoPulse™ IL-12, demonstrated a
favorable safety profile and evidence of anti-tumor activity in the
treatment of various skin cancers as well as the potential to
initiate a systemic immune response. ImmunoPulse™ IL-12 is
currently in clinical development for several indications,
including metastatic melanoma and triple-negative breast cancer. In
addition to ImmunoPulse™ IL-12, the Company is also seeking to
identify and develop new immune-targeting agents for use with the
ImmunoPulse™ platform. For more information, please visit
www.oncosec.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Forward-looking statements can be
identified by words such as "will," "can," and similar references
to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based on
management's current preliminary expectations and are subject to
risks and uncertainties, which may cause our results to differ
materially and adversely from the statements contained herein.
Potential risks and uncertainties that could cause actual results
to differ from those predicted include, among others, the
following: uncertainties inherent in pre-clinical studies and
clinical trials, such as the ability to enroll patients in clinical
trials and the risk of adverse events; unexpected new data,
safety and technical issues; our ability to raise additional
funding necessary to fund continued operations; and the other
factors discussed in OncoSec's filings with the Securities and
Exchange Commission.
Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
disclaims any obligation to update any forward-looking statements
to reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events.
Contact
Mary
Marolla
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Logo -
http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-announces-poster-presentation-with-heat-biologics-inc-at-the-american-association-for-cancer-research-aacr-annual-meeting-2016-300249618.html
SOURCE OncoSec Medical Incorporated